Earnings ·
Castle Biosciences reports Q3 revenue of $102.9M and raises full-year guidance to $385-395 million
CSTLCastle Biosciences Inc
Castle Biosciences reported third-quarter revenue of $102.9 million, a 24% increase from the prior year period, driven by a 47% surge in TissueCypher test volumes. The company posted an adjusted EBITDA of $12.7 million and generated $19.7 million in net cash from operations. Management raised its full-year 2026 revenue guidance to $385-395 million, up from the previous range of $365-375 million, while maintaining expectations for positive adjusted EBITDA through the end of 2027. Castle Biosciences operates in the medical diagnostics industry, developing and commercializing molecular tests that guide patient care decisions in dermatology and gastroenterology.